Volume 18, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We wished to evaluate the safety and anthelmintic efficacy for man of dichlorvos (Dichlorman®), a new anthelmintic compound. Clinical, parasitologic, and pharmacologic studies were conducted on 108 hospitalized adult patients. The drug was administered in a granular-resin formulation that permits slow liberation in the intestinal tract. Formalinether (MGL) and Stoll egg-count techniques were employed for evaluation of therapy at different dosage levels. A wide range of laboratory studies was done, with particular emphasis on plasma and red-cell cholinesterase determinations. Despite the fact that the drug caused reduction in plasma cholinesterase levels, no clinical side-effects were observed in the carefully monitored patients, except for brief mild headache in a few. Cure rates of infections, with a single oral dose of 12 mg per kilogram of body weight, were 85.7% for hookworm, 87.8% for , and 77.8% for ; egg-count reductions in the cases not completely cured were 97.3, 98.5, and 83.7 percent, respectively.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error